310 related articles for article (PubMed ID: 28038867)
1. Parkinsonian axial signs in schizophrenia.
Morgante F; Barbui C; Tinazzi M;
Parkinsonism Relat Disord; 2017 Mar; 36():89-92. PubMed ID: 28038867
[TBL] [Abstract][Full Text] [Related]
2. Imaging of the dopamine transporter predicts pattern of disease progression and response to levodopa in patients with schizophrenia and parkinsonism: a 2-year follow-up multicenter study.
Tinazzi M; Morgante F; Matinella A; Bovi T; Cannas A; Solla P; Marrosu F; Nicoletti A; Zappia M; Luca A; Di Stefano A; Morgante L; Pacchetti C; Minafra B; Sciarretta M; Dallocchio C; Rossi S; Ulivelli M; Ceravolo R; Frosini D; Cipriani A; Barbui C
Schizophr Res; 2014 Feb; 152(2-3):344-9. PubMed ID: 24369987
[TBL] [Abstract][Full Text] [Related]
3. [123I]-FP/CIT SPECT imaging for distinguishing drug-induced parkinsonism from Parkinson's disease.
Lorberboym M; Treves TA; Melamed E; Lampl Y; Hellmann M; Djaldetti R
Mov Disord; 2006 Apr; 21(4):510-4. PubMed ID: 16250023
[TBL] [Abstract][Full Text] [Related]
4. Individual parkinsonian motor signs and striatal dopamine transporter deficiency: a study with [I-123]FP-CIT SPECT.
Mäkinen E; Joutsa J; Jaakkola E; Noponen T; Johansson J; Pitkonen M; Levo R; Mertsalmi T; Scheperjans F; Kaasinen V
J Neurol; 2019 Apr; 266(4):826-834. PubMed ID: 30687897
[TBL] [Abstract][Full Text] [Related]
5. Parkinsonism in multiple system atrophy: natural history, severity (UPDRS-III), and disability assessment compared with Parkinson's disease.
Tison F; Yekhlef F; Chrysostome V; Balestre E; Quinn NP; Poewe W; Wenning GK
Mov Disord; 2002 Jul; 17(4):701-9. PubMed ID: 12210859
[TBL] [Abstract][Full Text] [Related]
6. [123I]FP-CIT SPET imaging in drug-induced Parkinsonism.
Tinazzi M; Ottaviani S; Isaias IU; Pasquin I; Steinmayr M; Vampini C; Pilleri M; Moretto G; Fiaschi A; Smania N; Giorgetti P; Antonini A
Mov Disord; 2008 Oct; 23(13):1825-9. PubMed ID: 18759353
[TBL] [Abstract][Full Text] [Related]
7. Beta-CIT-SPECT combined with UPDRS appears to distinguish different parkinsonian conditions.
Sjøholm H; Sundsfjord J; Mellgren SI
Acta Neurol Scand; 2002 Jan; 105(1):5-7. PubMed ID: 11903101
[TBL] [Abstract][Full Text] [Related]
8. Lower striatal dopamine transporter binding in neuroleptic-naive schizophrenic patients is not related to antipsychotic treatment but it suggests an illness trait.
Mateos JJ; Lomeña F; Parellada E; Mireia F; Fernandez-Egea E; Pavia J; Prats A; Pons F; Bernardo M
Psychopharmacology (Berl); 2007 Apr; 191(3):805-11. PubMed ID: 17019564
[TBL] [Abstract][Full Text] [Related]
9. Progression of dopaminergic degeneration in Parkinson's disease and atypical parkinsonism: a longitudinal beta-CIT SPECT study.
Pirker W; Djamshidian S; Asenbaum S; Gerschlager W; Tribl G; Hoffmann M; Brücke T
Mov Disord; 2002 Jan; 17(1):45-53. PubMed ID: 11835438
[TBL] [Abstract][Full Text] [Related]
10. Correlation of dopamine transporter imaging with parkinsonian motor handicap: how close is it?
Pirker W
Mov Disord; 2003 Oct; 18 Suppl 7():S43-51. PubMed ID: 14531046
[TBL] [Abstract][Full Text] [Related]
11. Factor structure of parkinsonian signs in the community-dwelling elderly.
Louis ED; Tang MX; Mayeux R
Mov Disord; 2004 Mar; 19(3):268-72. PubMed ID: 15022180
[TBL] [Abstract][Full Text] [Related]
12. Decreased striatal dopamine transporter binding assessed with [123I] FP-CIT in first-episode schizophrenic patients with and without short-term antipsychotic-induced parkinsonism.
Mateos JJ; Lomeña F; Parellada E; Font M; Fernandez E; Pavia J; Prats A; Pons F; Bernardo M
Psychopharmacology (Berl); 2005 Sep; 181(2):401-6. PubMed ID: 15830229
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic value of 123I-ioflupane and 123I-iodobenzamide SPECT scans in 248 patients with parkinsonian syndromes.
Vlaar AM; de Nijs T; Kessels AG; Vreeling FW; Winogrodzka A; Mess WH; Tromp SC; van Kroonenburgh MJ; Weber WE
Eur Neurol; 2008; 59(5):258-66. PubMed ID: 18264015
[TBL] [Abstract][Full Text] [Related]
14. Quetiapine use in a patient with chronic schizophrenia and severe parkinsonism.
Stoner SC; Lea JW; Wolf AL; Berges AA
Pharmacotherapy; 2005 Nov; 25(11):1651-5. PubMed ID: 16232027
[TBL] [Abstract][Full Text] [Related]
15. Does levodopa slow or hasten the rate of progression of Parkinson's disease?
Fahn S;
J Neurol; 2005 Oct; 252 Suppl 4():IV37-IV42. PubMed ID: 16222436
[TBL] [Abstract][Full Text] [Related]
16. Differences in nigro-striatal impairment in clinical variants of early Parkinson's disease: evidence from a FP-CIT SPECT study.
Rossi C; Frosini D; Volterrani D; De Feo P; Unti E; Nicoletti V; Kiferle L; Bonuccelli U; Ceravolo R
Eur J Neurol; 2010 Apr; 17(4):626-30. PubMed ID: 20050904
[TBL] [Abstract][Full Text] [Related]
17. [(18)F] FP-CIT PET study in parkinsonian patients with leukoaraiosis.
Lee MJ; Kim SL; Kim HI; Oh YJ; Lee SH; Kim HK; Han CS; Lyoo CH; Ryu YH; Lee MS
Parkinsonism Relat Disord; 2015 Jul; 21(7):704-8. PubMed ID: 25937616
[TBL] [Abstract][Full Text] [Related]
18. Striatal dopamine loss and discriminative sensory dysfunction in Parkinson's disease.
Lyoo CH; Ryu YH; Lee MJ; Lee MS
Acta Neurol Scand; 2012 Nov; 126(5):344-9. PubMed ID: 22380639
[TBL] [Abstract][Full Text] [Related]
19. High Prevalence of Early Parkinson's Disease in Patients With Subtle Parkinsonian Signs.
Sasaki S
Front Neurol; 2021; 12():656679. PubMed ID: 34305780
[No Abstract] [Full Text] [Related]
20. Chronic motor cortex stimulation in patients with advanced Parkinson's disease and effects on striatal dopaminergic transmission as assessed by 123I-FP-CIT SPECT: a preliminary report.
Di Giuda D; Calcagni ML; Totaro M; Cocciolillo F; Piano C; Soleti F; Fasano A; Cioni B; Bentivoglio AR; Giordano A
Nucl Med Commun; 2012 Sep; 33(9):933-40. PubMed ID: 22735298
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
